Review of Cardiotoxicity in Pediatric Cancer Patients: During and after Therapy

Review of Cardiotoxicity in Pediatric Cancer Patients: During and after Therapy

Bibliographic Details
Main Author:	Joy M. Fulbright
Format:	Article
Language:	English
Published:	Hindawi Limited 2011-01-01
Series:	Cardiology Research and Practice
Online Access:	http://dx.doi.org/10.4061/2011/942090

Similar Items

Tissue Doppler Imaging for anthracycline cardiotoxicity monitoring in pediatric patients with cancer
by: Francesco Venturelli, et al.
Published: (2018-09-01)

Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy
by: Anna Calleja, et al.
Published: (2015-01-01)

Exercise on the Mitigation of Anthracycline-Associated Cardiotoxic Effects in Pediatric Cancer Survivors: A Review
by: Vazquez, Danny Alberto, Jr.
Published: (2013)

Cancer therapy-induced cardiotoxicity: Review and algorithmic approach toward evaluation
by: K Purkayastha, et al.
Published: (2017-01-01)

Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention
by: Rui Adão, et al.
Published: (2013-05-01)

ECG Scoring for the Evaluation of Therapy-Naïve Cancer Patients to Predict Cardiotoxicity
by: Julia Pohl, et al.
Published: (2021-03-01)

Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy
by: Muthiah Vaduganathan, MD, MPH, et al.
Published: (2019-09-01)

Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review
by: Georgios Karvelas, et al.
Published: (2018-07-01)

Subclinical cardiotoxicity in cancer therapy: The impact of early detection
by: Ana G. Almeida
Published: (2017-01-01)

Cancer therapy and cardiotoxicity: The need of serial Doppler echocardiography
by: Pardo Moira, et al.
Published: (2007-01-01)

Gender differences in cardiotoxicities associated with immune checkpoint inhibitor therapy in cancer patients
by: Sheharyar Minhas, et al.
Published: (2020-01-01)

Acute Cardiotoxicity With Concurrent Trastuzumab and Hypofractionated Radiation Therapy in Breast Cancer Patients
by: Mutlay Sayan, et al.
Published: (2019-10-01)

Risk stratification and pattern of cardiotoxicity in pediatric Ewing sarcoma
by: Emad Moussa, et al.
Published: (2017-03-01)

Cardiotoxicity after cancer treatment: a process map of the patient treatment journey
by: Robyn A. Clark, et al.
Published: (2019-08-01)

Effect of Renal Function on the Development of Cardiotoxicity in Early Breast Cancer Patients with Anti-cancer Therapy
by: Wan-Jyun Ciou, et al.
Published: (2017)

Cardiotoxicity of cancer therapeutics: current issues in screening, prevention and therapy
by: Richard Joseph Sheppard, et al.
Published: (2013-03-01)

The genetics of anthracycline-induced cardiotoxicity in cancer patients
by: Naidoo, Horacia
Published: (2018)

A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients
by: Erika Matos, et al.
Published: (2016-01-01)

Early cardiotoxicity after adjuvant concomitant treatment with radiotherapy and trastuzumab in patients with breast cancer
by: Marinko Tanja, et al.
Published: (2018-02-01)

Cardiotoxicity of Novel Targeted Hematological Therapies
by: Valentina Giudice, et al.
Published: (2020-12-01)

Examining Cardiotoxicity With HER2 Therapies∗
by: Neelima Denduluri, MD
Published: (2020-06-01)

Cardiotoxicity in anthracycline therapy: Prevention strategies
by: Margarida Cruz, et al.
Published: (2016-06-01)

Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia
by: Radu Letitia Elena, et al.
Published: (2020-04-01)

The prospects for applications of cardiometric approach in evaluation of cardiotoxicity under Anthracyclines therapy in patients with breast cancer
by: Alla I. Shikhlyarova, et al.
Published: (2018-11-01)

Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome
by: Iacopo Fabiani, et al.
Published: (2020-08-01)

An International Survey of Health Care Providers Involved in the Management of Cancer Patients Exposed to Cardiotoxic Therapy
by: Jeffrey Sulpher, et al.
Published: (2015-01-01)

The cost-effectiveness of cardiac monitoring in breast cancer patients who have received cardiotoxic therapies
by: Mann, Teresa A.
Published: (2012)

Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy
by: Anthony F. Yu, MD, et al.
Published: (2020-06-01)

Assessing cardiotoxicity in randomised trials of anthracycline in cancer patients
by: Kerr, Amanda J.
Published: (2015)

NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients
by: Isabel Blancas, et al.
Published: (2020-12-01)

Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology
by: Hasan Kobat, et al.
Published: (2021-02-01)

Natural Products Counteracting Cardiotoxicity during Cancer Chemotherapy: The Special Case of Doxorubicin, a Comprehensive Review
by: Izabela Koss-Mikołajczyk, et al.
Published: (2021-09-01)

Review on the pathophysiology of anthracycline-induced cardiotoxicity
by: Tiago Alexandre de Oliveira Valente
Published: (2019)

5-fluorouracil and cardiotoxicity: a review
by: Jaskanwal D. Sara, et al.
Published: (2018-06-01)

Cardiotoxicity of Plants in Iran: a Review
by: Mohammad R. Aslani
Published: (2018-06-01)

Cardiotoxicity of Plants in Iran: a Review
by: Mohammad Reza Aslani
Published: (2018-10-01)

Evaluation of cardiotoxicity five years after 2D planned, non-simulated, radiation therapy for left breast cancer
by: Kyriaki Pistevou-Gompaki, et al.
Published: (2008-10-01)

Cardio-Oncology and the Intersection of Cancer and Cardiotoxicity
by: Richard K. Cheng, MD, MSc, et al.
Published: (2019-12-01)

NT-proBNP as Early Marker of Subclinical Late Cardiotoxicity after Doxorubicin Therapy and Mediastinal Irradiation in Childhood Cancer Survivors
by: Amal Zidan, et al.
Published: (2015-01-01)

Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.
by: Valentina K Todorova, et al.
Published: (2016-01-01)